Magellan Asset Management Ltd Cuts Position in Zimmer Biomet Holdings, Inc. $ZBH

Posted by Geri Gentry on Jul 22nd, 2026

Magellan Asset Management Ltd decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 13.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 550,781 shares of the medical equipment provider’s stock after selling 85,953 shares during the quarter. Magellan Asset Management Ltd’s holdings in Zimmer Biomet were worth $49,802,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its position in shares of Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares during the last quarter. Morningstar Investment Management LLC lifted its position in shares of Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after purchasing an additional 40,610 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Zimmer Biomet by 257.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after purchasing an additional 24,748 shares in the last quarter. Douglas Lane & Associates LLC increased its holdings in Zimmer Biomet by 6.7% in the fourth quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider’s stock valued at $41,379,000 after buying an additional 28,818 shares during the last quarter. Finally, CIBC Asset Management Inc raised its stake in Zimmer Biomet by 67.6% in the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock valued at $4,183,000 after buying an additional 18,769 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ZBH shares. Barclays decreased their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. Weiss Ratings lowered Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. BMO Capital Markets assumed coverage on Zimmer Biomet in a research note on Wednesday, July 8th. They set a “market perform” rating and a $95.00 target price for the company. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. Finally, Stifel Nicolaus lowered their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $100.70.

View Our Latest Analysis on ZBH

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $88.94 on Wednesday. The company has a market capitalization of $17.21 billion, a P/E ratio of 23.10, a PEG ratio of 2.64 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The business has a 50 day simple moving average of $87.48 and a 200-day simple moving average of $89.81. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the previous year, the company posted $1.81 EPS. The company’s quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 24.94%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.